Literature DB >> 28025946

Proteolytic Cleavage of Polyglutamine Disease-Causing Proteins: Revisiting the Toxic Fragment Hypothesis.

Carlos A Matos1, Luis Pereira de Almeida2, Clevio Nobrega3.   

Abstract

Proteolytic cleavage has been implicated in the pathogenesis of diverse neurodegenerative diseases involving abnormal protein accumulation. Polyglutamine diseases are a group of nine hereditary disorders caused by an abnormal expansion of repeated glutamine tracts contained in otherwise unrelated proteins. When expanded, these proteins display toxic properties and are prone to aggregate, but the mechanisms responsible for the selective neurodegeneration observed in polyglutamine disease patients are still poorly understood. It has been suggested that the neuronal toxicity of polyglutamine-expanded proteins is associated with the production of deleterious protein fragments. This review aims at discussing the involvement of proteolytic cleavage in the six types of spinocerebellar ataxia caused by polyglutamine expansion of proteins. The analysis takes into detailed consideration evidence concerning fragment detection and the mechanisms of fragment toxicity. Current evidence suggests that the proteins involved in spinocerebellar ataxia types 3, 6 and 7 give rise to stable proteolytic fragments. Fragments carrying polyglutamine expansions display increased tendency to aggregate and toxicity, comparing with their non-expanded counterparts or with the correspondent full-length expanded proteins. Data concerning spinocerebellar ataxia types 1, 2 and 17 is still scarce, but available results afford further investigation. Available literature suggests that proteolytic cleavage of expanded polyglutamine-containing proteins enhances toxicity in disease-associated contexts and may constitute an important step in the pathogenic cascade of polyglutamine diseases. Countering protein fragmentation thus presents itself as a promising therapeutic aim. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Neurodegenerative diseases; ataxin-3; ataxin-7; machado-joseph disease; polyglutamine diseases; proteolytic cleavage; spinocerebellar ataxia; toxiczzm321990fragments; voltage-dependent P/Q-type calcium channel subunit alpha-1A

Mesh:

Substances:

Year:  2017        PMID: 28025946     DOI: 10.2174/1381612822666161227121912

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  10 in total

1.  Calpain Inhibition Is Protective in Machado-Joseph Disease Zebrafish Due to Induction of Autophagy.

Authors:  Maxinne Watchon; Kristy C Yuan; Nick Mackovski; Adam J Svahn; Nicholas J Cole; Claire Goldsbury; Silke Rinkwitz; Thomas S Becker; Garth A Nicholson; Angela S Laird
Journal:  J Neurosci       Date:  2017-07-07       Impact factor: 6.167

2.  Calpain-1 ablation partially rescues disease-associated hallmarks in models of Machado-Joseph disease.

Authors:  Jonasz J Weber; Eva Haas; Yacine Maringer; Stefan Hauser; Nicolas L P Casadei; Athar H Chishti; Olaf Riess; Jeannette Hübener-Schmid
Journal:  Hum Mol Genet       Date:  2020-04-15       Impact factor: 6.150

Review 3.  Chaperones in Polyglutamine Aggregation: Beyond the Q-Stretch.

Authors:  E F E Kuiper; Eduardo P de Mattos; Laura B Jardim; Harm H Kampinga; Steven Bergink
Journal:  Front Neurosci       Date:  2017-03-23       Impact factor: 4.677

Review 4.  Killing Two Angry Birds with One Stone: Autophagy Activation by Inhibiting Calpains in Neurodegenerative Diseases and Beyond.

Authors:  Jonasz Jeremiasz Weber; Priscila Pereira Sena; Elisabeth Singer; Huu Phuc Nguyen
Journal:  Biomed Res Int       Date:  2019-02-14       Impact factor: 3.411

5.  PolyQ-expanded proteins impair cellular proteostasis of ataxin-3 through sequestering the co-chaperone HSJ1 into aggregates.

Authors:  Hong-Wei Yue; Jun-Ye Hong; Shu-Xian Zhang; Lei-Lei Jiang; Hong-Yu Hu
Journal:  Sci Rep       Date:  2021-04-09       Impact factor: 4.379

Review 6.  Current Status of Gene Therapy Research in Polyglutamine Spinocerebellar Ataxias.

Authors:  Ricardo Afonso-Reis; Inês T Afonso; Clévio Nóbrega
Journal:  Int J Mol Sci       Date:  2021-04-19       Impact factor: 5.923

7.  Calpains as novel players in the molecular pathogenesis of spinocerebellar ataxia type 17.

Authors:  Jonasz Jeremiasz Weber; Stefanie Cari Anger; Priscila Pereira Sena; Rana Dilara Incebacak Eltemur; Chrisovalantou Huridou; Florian Fath; Caspar Gross; Nicolas Casadei; Olaf Riess; Huu Phuc Nguyen
Journal:  Cell Mol Life Sci       Date:  2022-04-28       Impact factor: 9.207

8.  KPNB1 modulates the Machado-Joseph disease protein ataxin-3 through activation of the mitochondrial protease CLPP.

Authors:  Jonasz Jeremiasz Weber; Priscila Pereira Sena; Mahkameh Abeditashi; Ana Velic; Maria Kalimeri; Rana Dilara Incebacak Eltemur; Jana Schmidt; Jeannette Hübener-Schmid; Stefan Hauser; Boris Macek; Olaf Riess; Thorsten Schmidt
Journal:  Cell Mol Life Sci       Date:  2022-07-06       Impact factor: 9.207

9.  The Truncated C-terminal Fragment of Mutant ATXN3 Disrupts Mitochondria Dynamics in Spinocerebellar Ataxia Type 3 Models.

Authors:  Jung-Yu Hsu; Yu-Ling Jhang; Pei-Hsun Cheng; Yu-Fan Chang; Su-Han Mao; Han-In Yang; Chia-Wei Lin; Chuan-Mu Chen; Shang-Hsun Yang
Journal:  Front Mol Neurosci       Date:  2017-06-20       Impact factor: 5.639

Review 10.  Roles of Post-translational Modifications in Spinocerebellar Ataxias.

Authors:  Linlin Wan; Keqin Xu; Zhao Chen; Beisha Tang; Hong Jiang
Journal:  Front Cell Neurosci       Date:  2018-09-19       Impact factor: 5.505

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.